» Sarepta Therapeutics Announces First Patient Dosed in Study of Non-Ambulant Patients with DMD Action Duchenne: "On the 12th of November, Sarepta announced the initiation for dosing in the 204 clinical study for non-ambulant and advanced DMD patients. The link to the official press release can be found here: http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=1989115
This study includes around 20 patients treated with eteplirsen whom can particularly be treated with exon 51 skipping. The investigation is being carried out in the United States and the major aims are to evaluate the safety of eteplirsen in DMD patients over a dosing time period of 96 weeks."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment